You have not created a stock watchlist. Create one now to track $ITCI!
Intracellular Th
Health Care
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule … more
Conversation Volume
Last 60 days
There is not enough conversation volume about this stock
Key Opinion Leaders
Strongest 30-day focus on $ITCI by total mentions
Loading data...
Real-time Chart
Price Chart for $ITCI
Conviction History
Bullish vs Bearish Conviction over the last 30 days.
This color denotes Market Hours (US/Eastern)
There is not enough conversation volume about this stock
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, heart failure, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
We've detected you're running a Microsoft browser so features may not work as expected. We strongly recommend you run Captain runs on the latest versions of Google Chrome, Firefox, or Safari.